Compare Stocks: APM, DARE, and TVRD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APM Aptorum Group	$0.67 -4.6%	$5.04	$0.60 ▼ $4.47	$4.24M	0.38	57,956 shs	167,078 shs
DARE Dare Bioscience	$0.77 +0.2%	$0.88	$0.69 ▼ $3.78	$15.19M	1.01	239,837 shs	69,570 shs
TVRD Tvardi Therapeutics	$1.03 -4.6%	$1.65	$0.93 ▼ $43.65	$14.41M	0.38	246,079 shs	130,294 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APM Aptorum Group	0.00%	0.00%	0.00%	-91.60%	-97.23%
DARE Dare Bioscience	+0.16%	-8.23%	+7.42%	-61.71%	-66.23%
TVRD Tvardi Therapeutics	-4.63%	-10.43%	-44.32%	-68.60%	-97.42%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APM Aptorum Group	$0.67 -4.6%	$5.04	$0.60 ▼ $4.47	$4.24M	0.38	57,956 shs	167,078 shs
DARE Dare Bioscience	$0.77 +0.2%	$0.88	$0.69 ▼ $3.78	$15.19M	1.01	239,837 shs	69,570 shs
TVRD Tvardi Therapeutics	$1.03 -4.6%	$1.65	$0.93 ▼ $43.65	$14.41M	0.38	246,079 shs	130,294 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APM Aptorum Group	0.00%	0.00%	0.00%	-91.60%	-97.23%
DARE Dare Bioscience	+0.16%	-8.23%	+7.42%	-61.71%	-66.23%
TVRD Tvardi Therapeutics	-4.63%	-10.43%	-44.32%	-68.60%	-97.42%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APM Aptorum Group	1.00	Sell	N/A	N/A
DARE Dare Bioscience	2.33	Hold	$6.50	740.44% Upside
TVRD Tvardi Therapeutics	2.78	Moderate Buy	$18.00	1,647.57% Upside

Current Analyst Ratings Breakdown

Latest APM, DARE, and TVRD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	TVRD Tvardi Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/16/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/14/2026	DARE Dare Bioscience	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$1.00
9/8/2026	TVRD Tvardi Therapeutics	Lucid Cap Mkts Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/25/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	DARE Dare Bioscience	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	DARE Dare Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/30/2026	TVRD Tvardi Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00
7/17/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/16/2026	APM Aptorum Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APM Aptorum Group	$430K	9.86	N/A	N/A	$2.17 per share	0.31
DARE Dare Bioscience	$1.03M	14.77	N/A	N/A	$0.20 per share	3.87
TVRD Tvardi Therapeutics	$7.14M	1.92	N/A	N/A	$2.23 per share	0.46

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APM Aptorum Group	-$1.36M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	-$13.40M	-$0.70	N/A	N/A	N/A	-803.80%	-748.30%	-38.75%	11/12/2026 (Estimated)
TVRD Tvardi Therapeutics	-$18.21M	-$2.79	N/A	N/A	N/A	N/A	-145.40%	-91.11%	N/A

Latest APM, DARE, and TVRD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2026	Q2 2026	TVRD Tvardi Therapeutics	-$0.65	-$0.69	-$0.04	-$0.69	N/A	N/A
8/13/2026	Q2 2026	DARE Dare Bioscience	-$0.2967	-$0.20	+$0.0967	-$0.20	$0.00 million	$0.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APM Aptorum Group	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APM Aptorum Group	N/A	0.78	0.78
DARE Dare Bioscience	N/A	0.99	0.99
TVRD Tvardi Therapeutics	N/A	1.87	1.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APM Aptorum Group	3.80%
DARE Dare Bioscience	6.70%
TVRD Tvardi Therapeutics	44.66%

Insider Ownership

Company	Insider Ownership
APM Aptorum Group	63.99%
DARE Dare Bioscience	4.10%
TVRD Tvardi Therapeutics	7.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APM Aptorum Group	30	6.35 million	2.29 million	Not Optionable
DARE Dare Bioscience	24	19.67 million	18.86 million	Not Optionable
TVRD Tvardi Therapeutics	80	13.34 million	12.35 million	N/A

APM, DARE, and TVRD Headlines

Recent News About These Companies

Tvardi Therapeutics (NASDAQ:TVRD) Stock Bumped Up to "Sell" by Wall Street Zen

October 4, 2026 | americanbankingnews.com

Tvardi Therapeutics (NASDAQ:TVRD) & Phibro Animal Health (NASDAQ:PAHC) Financial Contrast

October 1, 2026 | americanbankingnews.com

Forumsbeiträge zu Tvardi Therapeutics Inc. Registered shs

September 27, 2026 | finanzen.atF

Tvardi pubblica dati preclinici su inibitore STAT3 per la colite

September 25, 2026 | it.investing.com

New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)

September 25, 2026 | finance.yahoo.com

Tvardi Therapeutics, Inc. Announces Publication Of Preclinical Data Evaluating Its STAT3 Inhibitor In Ulcerative Colitis

September 25, 2026 | marketscreener.comM

New Preclinical Data Further Support Potential for Tvardi's STAT3 Inhibitors in Ulcerative Colitis (UC)

September 24, 2026 | globenewswire.com

Tvardi Therapeutics, Inc.(NasdaqCM:TVRD) dropped from S&P Global BMI Index

September 21, 2026 | marketscreener.comM

Tvardi Therapeutics Consensus Price Target Increased by 11.76% to $9.69

September 15, 2026 | msn.com

Tvardi Therapeutics to Participate in Upcoming Investor Events

August 26, 2026 | globenewswire.com

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

August 14, 2026 | globenewswire.com

Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026

August 12, 2026 | globenewswire.com

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109, Plans 2027 Clinical Trial

July 30, 2026 | quiverquant.comQ

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

July 30, 2026 | globenewswire.com

Tvardi Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:TVRD

July 23, 2026 | benzinga.com

Tvardi Therapeutics Inc TVRD

July 14, 2026 | morningstar.comM

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD), Teva Pharmaceutical (TEVA) and BridgeBio Pharma (BBIO)

July 10, 2026 | theglobeandmail.com

TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know

July 9, 2026 | zacks.com

Tvardi Therapeutics Reports Phase 1 Data for TTI-109

July 8, 2026 | theglobeandmail.com

Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109

July 7, 2026 | investorideas.comI

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, DARE, and TVRD Company Descriptions

Aptorum Group NASDAQ:APM

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

Dare Bioscience NASDAQ:DARE

$0.77 +0.00 (+0.16%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.77 -0.01 (-0.83%)

As of 10/9/2026 07:08 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Tvardi Therapeutics NASDAQ:TVRD

$1.03 -0.05 (-4.63%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.03 +0.00 (+0.49%)

As of 10/9/2026 07:30 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APM, DARE, and TVRD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APM, DARE, and TVRD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APM, DARE, and TVRD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, DARE, and TVRD Company Descriptions

Aptorum Group NASDAQ:APM

Dare Bioscience NASDAQ:DARE

Tvardi Therapeutics NASDAQ:TVRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APM, DARE, and TVRD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APM, DARE, and TVRD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APM, DARE, and TVRD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, DARE, and TVRD Company Descriptions

Aptorum Group NASDAQ:APM

Dare Bioscience NASDAQ:DARE

Tvardi Therapeutics NASDAQ:TVRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools